Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 20/20 | 0.78 |
| ▸ | BRD2 | P25440 | 1/20 | 0.74 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.74 |
| ▸ | TSPO | P30536 | 1/20 | 0.74 |
| ▸ | EP300 | Q09472 | 1/20 | 0.74 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.74 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28497330 | 0.89 | BRD4 (0.82) | BRD4BRD2ADORA2BTSPOEP300 | |
| SCHEMBL16339652 | 0.87 | BRD4 (1.00) | BRD4BRD2ADORA2BTSPOEP300 | |
| SCHEMBL15069412 | 0.87 | BRD4 (1.00) | BRD4BRD2ADORA2BTSPOEP300 | |
| SCHEMBL29745765 | 0.87 | BRD4 (1.00) | BRD4BRD2ADORA2BTSPOEP300 | |
| SCHEMBL16339997 | 0.87 | BRD4 (1.00) | BRD4BRD2ADORA2BTSPOEP300 | |
| SCHEMBL16340352 | 0.86 | BRD4 (1.00) | BRD4BRD2ADORA2BTSPOEP300 | |
| SCHEMBL16340222 | 0.86 | BRD4 (1.00) | BRD4BRD2ADORA2BTSPOEP300 | |
| Mivebresib SCHEMBL29362711 | 0.85 | BRD4 (1.00) | BRD4BRD2ADORA2BTSPOEP300 | |
| Mivebresib SCHEMBL29430453 | 0.85 | BRD4 (1.00) | BRD4BRD2ADORA2BTSPOEP300 | |
| Mivebresib SCHEMBL15068241 | 0.85 | BRD4 (1.00) | BRD4BRD2ADORA2BTSPOEP300 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190084981-A1 | Bromodomain Inhibitors | ABBVIE INC (US) | 2019-03-21 | — | — | US | disclosed |
| US-10131657-B2 | Bromodomain inhibitors | ABBVIE INC. (US) | 2018-11-20 | — | — | US | disclosed |
| US-9957263-B2 | Bromodomain inhibitors | ABBVIE INC. (US) | 2018-05-01 | — | — | US | disclosed |
| US-20160272630-A1 | Bromodomain Inhibitors | ABBVIE INC. (US) | 2016-09-22 | — | — | US | disclosed |
| US-20160185769-A1 | Bromodomain Inhibitors | ABBVIE INC. (US) | 2016-06-30 | — | — | US | disclosed |
| EP-3013827-A1 | BROMODOMAIN INHIBITORS | AbbVie Inc. (US) | 2016-05-04 | — | — | EP | disclosed |
| EP-3013828-A1 | BROMODOMAIN INHIBITORS | AbbVie Inc. (US) | 2016-05-04 | — | — | EP | disclosed |
| WO-2014206150-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC. (US) | 2014-12-31 | — | — | WO | disclosed |
| WO-2014206345-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC. (US) | 2014-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190084981-A1 | Bromodomain Inhibitors | BRD4, BRD1, BRD3 | BRD4 1/4885BRD2 8/4885ADORA2B 1667/4885 |
| US-10131657-B2 | Bromodomain inhibitors | BRD1, BRD4, BRD3 | BRD4 2/4885BRD2 8/4885ADORA2B 1257/4885 |
| US-20160272630-A1 | Bromodomain Inhibitors | BRD4, BRDT, EP300 | BRD4 1/4885BRD2 7/4885ADORA2B 4552/4885 |
| US-20160185769-A1 | Bromodomain Inhibitors | BRD1, BRD4, BRD3 | BRD4 2/4885BRD2 8/4885ADORA2B 1257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.